GlassScriptPhysician profile
Stanton S Lebouitz
NPI 1255322798
$16,772.16
in general payments reported to CMS, 2019-2025
42 companies · $2,818 in 2025
The $2,818 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,163 · 2020: $1,783 · 2021: $1,675 · 2022: $1,501 · 2023: $2,900 · 2024: $2,931 · 2025: $2,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,303 · Education: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,302.81 |
| Education | $346.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,884.72 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $2,068.34 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,506.37 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,012.07 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Sun Pharmaceutical Industries INC. | $986.39 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $889.38 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $869.97 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $825.72 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $732.36 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $619.51 | 2019-2021 | |
| Ucb, INC. | $562.98 | 2019-2025 | Bimzelx, Cimzia |
| Allergan, INC. | $546.75 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $411.29 | 2020-2021 | |
| Incyte Corporation | $322.54 | 2022-2025 | Opzelura |
| Pfizer INC. | $266.10 | 2019-2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanton Lebouitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.